Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 19, Issue SUPPL. 2, 2008, Pages

  Horwich, A ^a,c   Parker, C ^a,c   Kataja, V ^b,c  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c ESMO HEAD OFFICE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIANDROGEN; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; DOCETAXEL; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BONE METASTASIS; BONE PAIN; BONE SCINTISCANNING; CANCER INCIDENCE; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIGITAL RECTAL EXAMINATION; EVIDENCE BASED MEDICINE; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; ORCHIECTOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; INCIDENCE; MALE; METASTASIS; PATHOLOGY; PROSTATE TUMOR;

FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; NEOPLASM METASTASIS; NEOPLASM STAGING; PROSTATIC NEOPLASMS;

EID: 45149131449     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn084     Document Type: Article

References (19)

1. Draisma G, Boer R, Otto SJ et al. Lead times and overdetecton due to prostate-specific antigen screening: Estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95: 868-878.
2. Thompson IM, Ankerst DP, Chi C et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006; 98: 529-534.
3. Gleave ME, Coupland D, Drachenberg D et al. Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. Urology 1996; 47: 708-712.
4. Partin AW, Mangold LA, Lamm DM et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001; 58: 843-848.
5. Lu Yao GL, Yao S-L. Population based study of long-term survival in patents with clinically localised prostate cancer. Lancet 1997; 349: 906-910.
6. Bill-Axelson, Holmberg L, Ruutu M et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005; 352: 1977-1984.
7. Klotz L. Active surveillance with selective delayed intervention: Using natural history to guide treatment in good risk prostate cancer. J Urol 2004; 172: S48-S51.
8. Dearnaley DP, Khoo VS, Norman AR et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: A randomised trial. Lancet 1999; 353: 267-272.
9. Bolla M, van Poppel H, Collette L et al. Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). Lancet 2005; 366: 572-578.
10. Lawton CA, Winter K, Murray K et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavourable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 49: 937-946.
11. Pilepich MV, Winter K, John MJ et al. Phase III radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjunct to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50: 1243-1252.
12. DAmico AV, Manda J, Loffredo M et al. 6-month androgen suppression plus radiation therapy versus radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 2004; 292: 821-827.
13. Denham JW, Steigler A, Lamb DS et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005; 6: 841-850.
14. Widmark A, Fosså SD, Lund MP et al. Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patents in the randomized Scandinavian trial SPCG-7/SFUO-3. Urology 2003; 61: 145-151.
15. Tannock IF, de Witt R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
16. Petrylak DP, Tangen C, Hussain M et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520.
17. Porter AT, McEwan AJ, Powe JE et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993; 25: 805-813.
18. Quilty P, Kirk D, Bolger JJ et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994; 31: 33-40.
19. Saad F, Gleason DM, Murray R et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complicatons in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879-882.